CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

Rhea-AI Summary

CytoSorbents (NASDAQ: CTSO) has received $1.7 million in cash proceeds from selling its 2023 and amended 2022 Net Operating Loss (NOL) and R&D tax credits through the New Jersey Technology Business Tax Certificate Transfer Program. The non-dilutive funding, sponsored by the New Jersey Economic Development Authority (NJEDA), will support:

• Preparations for DrugSorb™-ATR launch in the U.S. and Canada
• Manufacturing scale-up at the new Princeton facility
• Other strategic initiatives

The program enables approved Technology and Biotechnology Businesses to sell their unused NOL and R&D Tax Credits for at least 80% of the value to profitable NJ corporate taxpayers. Due to New Jersey's tax reform legislation A.B. 5323 enacted on July 3, 2023, CytoSorbents amended its 2022 return, increasing the NOL amount available for sale.

Positive

• Received $1.7M in non-dilutive funding strengthening cash reserves
• Secured additional NOL credits through 2022 tax return amendment
• Funding supports upcoming DrugSorb™-ATR product launch and manufacturing expansion

Negative

• Continued operating losses indicated by the need to sell NOL credits

Insights

Financial Analyst

CytoSorbents secured $1.7M in non-dilutive funding through NJ tax credits, strengthening its balance sheet to support product launches without shareholder dilution.

This $1.7 million cash infusion represents an efficient financial maneuver by CytoSorbents, converting non-cash assets (tax losses and R&D credits) into immediate working capital. For a company with a $60.75M market cap, this amount represents approximately 2.8% of their total market value.

The funding comes through New Jersey's Technology Business Tax Certificate Transfer Program, which allows qualifying biotech companies to monetize accumulated tax losses and R&D investments - a particularly valuable mechanism for pre-profit firms in this sector that typically accumulate substantial losses during development phases.

What makes this capital especially valuable is its non-dilutive nature - unlike equity financing that would decrease existing shareholders' ownership percentages, this funding maintains the current capital structure while bolstering liquidity. The company has specified three uses for these funds:

• Preparation for the anticipated launch of DrugSorb™-ATR in the U.S. and Canada
• Scaling up manufacturing at their new Princeton facility
• Supporting other strategic initiatives

CytoSorbents demonstrated financial acumen by leveraging the July 2023 New Jersey tax reform that retroactively allowed immediate deduction of R&E expenditures. This enabled them to amend their 2022 return, increasing available NOLs for monetization. The CFO's statement about remaining "active participants" indicates they view this program as a recurring potential source of non-dilutive capital.

For medical technology companies that require substantial ongoing capital for development and commercialization efforts, this type of funding represents efficient financial management, providing additional working capital without compromising their capital structure or future financing flexibility.

PRINCETON, N.J., April 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received $1.7 million in cash proceeds from the sale of its 2023 and amended 2022 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority (NJEDA).

CytoSorbents strengthens balance sheet with $1.7M cash from the NJ Technology Business Tax Certificate Transfer Program

"We are grateful for the opportunity to once again collaborate with the New Jersey Economic Development Authority to convert our state NOLs and R&D tax credits into non-dilutive funding that strengthens our cash reserves," said Peter J. Mariani, Chief Financial Officer of CytoSorbents. "This funding will help drive our ongoing growth, including preparations for the anticipated launch of DrugSorb^™-ATR in the U.S. and Canada, scaling up manufacturing at our new Princeton facility, and supporting other key strategic initiatives. We fully intend to remain active participants in this forward-thinking NJEDA program and are thankful for their continued support as we advance our mission to develop and commercialize life-saving technologies."

The New Jersey Technology Business Tax Certificate Transfer Program enables approved Technology and Biotechnology Businesses with Net Operating Losses to sell their Unused Net Operating Loss (NOL) and Unused Research and Development Tax Credits (R&D Tax Credits) for at least 80% of the value of the tax benefits to a profitable corporate taxpayer in the State of New Jersey that is not an Affiliated Business. This allows technology and biotechnology businesses with net operating losses to turn their tax losses and credits into cash to buy equipment or facilities, or for other allowable expenditures. The New Jersey Economic Development Authority (NJEDA) determines eligibility, and the New Jersey Division of Taxation determines the value of the tax benefits (NOL and R&D Tax Credits). 

On July 3, 2023, New Jersey enacted tax reform legislation, A.B. 5323, containing a provision that retroactively allowed taxpayers in New Jersey to immediately deduct from Research and Experimental (R&E) expenditures for which a state R&D credit is claimed. The legislation was retroactive to periods beginning January 1, 2022. As a result of this legislation, CytoSorbents amended its return for the year ended December 31, 2022, which increased the amount of NOL available for sale in the NJEDA Program. 

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

CytoSorbents' lead product, CytoSorb^®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 270,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved or cleared in the United States.

In the U.S. and Canada, CytoSorbents is developing the DrugSorb^™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. In September 2024, the Company submitted a De Novo medical device application to the U.S. FDA requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the antithrombotic drug ticagrelor, which was accepted for substantive review in October 2024. In November 2024, the Company received its MDSAP certification and submitted its Medical Device License (MDL) application to Health Canada. DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively. 

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY^®, CytoSorb-XL^™, HemoDefend-RBC^™, HemoDefend-BGA^™, VetResQ^®, K+ontrol^™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company's website at https://ir.cytosorbents.com/ or follow us on Facebook and X. 

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2025, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and X

U.S. Company Contact: 
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
pmariani@cytosorbents.com 

Investor Relations Contact:
Aman Patel, CFA & Adanna G. Alexander, PhD
ICR Healthcare 
ir@cytosorbents.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cytosorbents-receives-approximately-1-7-million-from-the-new-jersey-business-tax-certificate-transfer-program-302433093.html

SOURCE CytoSorbents Corporation

FAQ

How much funding did CytoSorbents (CTSO) receive from the NJ Tax Certificate Transfer Program in 2025?

CytoSorbents received $1.7 million in cash proceeds from selling its 2023 and amended 2022 NOL and R&D tax credits through the program.

What will CytoSorbents use the $1.7M NJEDA funding for?

The funding will support DrugSorb™-ATR launch preparations in U.S. and Canada, scaling up manufacturing at the Princeton facility, and other strategic initiatives.

How does the NJ Technology Business Tax Certificate Transfer Program benefit CTSO?

The program allows CytoSorbents to convert tax losses and R&D credits into non-dilutive cash funding, which can be used for equipment, facilities, or other allowable expenditures.

What impact did New Jersey's A.B. 5323 tax reform have on CTSO's NOL credits?

The legislation, enacted July 3, 2023, allowed CytoSorbents to amend its 2022 return, increasing the amount of NOL available for sale in the NJEDA Program.